Insulin syringe: difference between revisions
Diff·revision 11 → 12·20:18, 30 Nov 2024
Difference between revision 11 and revision 12 of Insulin syringe. 12 lines changed; the page grew by 758 bytes.
| Revision 11 — 02:02, 15 Nov 2024 DrTitration (talk) add the cross-link to the calculator page 2,889 bytes +99 | Revision 12 — 20:18, 30 Nov 2024 VerifyFirstVida (talk) state the syringe graduation the unit figure assumes 3,647 bytes +758 | ||
|---|---|---|---|
| 1 | {{Infobox concept | 1 | {{Infobox concept |
| 2 | | name = Insulin syringe | 2 | | name = Insulin syringe |
| + | 3 | | subtitle = Administration device | |
| 3 | | image = syringe.svg | 4 | | image = syringe.svg |
| 4 | | caption = Graduations are in insulin units; the unit is defined against U-100 insulin, not against volume. | 5 | | caption = Graduations are in insulin units; the unit is defined against U-100 insulin, not against volume. |
| ⋮ | ⋮ | ||
| 23 | [[Syringe dead space|Dead space]] — the volume retained in the hub and needle after the plunger is fully depressed — is a separate consideration and is proportionally larger for small doses. Low-dead-space designs reduce it substantially.{{r|iso7886}} | 24 | [[Syringe dead space|Dead space]] — the volume retained in the hub and needle after the plunger is fully depressed — is a separate consideration and is proportionally larger for small doses. Low-dead-space designs reduce it substantially.{{r|iso7886}} |
| 24 | 25 | ||
| + | 26 | == The unit convention == | |
| + | 27 | | Syringe marking | Volume | At 5 mg/mL | At 2.5 mg/mL | | |
| + | 28 | |---|---|---|---| | |
| + | 29 | | 5 U | 0.05 mL | 250 μg | 125 μg | | |
| + | 30 | | 10 U | 0.10 mL | 500 μg | 250 μg | | |
| + | 31 | | 20 U | 0.20 mL | 1,000 μg | 500 μg | | |
| + | 32 | | 40 U | 0.40 mL | 2,000 μg | 1,000 μg | | |
| + | 33 | ||
| + | 34 | The table is arithmetic, not guidance. It illustrates that a syringe marking corresponds to a mass only through a concentration, and that the concentration is itself uncertain unless the actual peptide mass in the vial is known — see [[Reconstitution of lyophilised peptides]] and [[Peptide content]].{{r|usp1503}} | |
| + | 35 | ||
| 25 | == References == | 36 | == References == |
| 26 | {{reflist}} | 37 | {{reflist}} |
| ⋮ | ⋮ | ||
| 28 | <ref name="iso7886">ISO 7886-1:2017, ''Sterile hypodermic syringes for single use — Part 1: Syringes for manual use''.</ref> | 39 | <ref name="iso7886">ISO 7886-1:2017, ''Sterile hypodermic syringes for single use — Part 1: Syringes for manual use''.</ref> |
| 29 | <ref name="usp797">United States Pharmacopeia, General Chapter <797>, ''Pharmaceutical Compounding — Sterile Preparations''.</ref> | 40 | <ref name="usp797">United States Pharmacopeia, General Chapter <797>, ''Pharmaceutical Compounding — Sterile Preparations''.</ref> |
| + | 41 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 30 | 42 | ||
| 31 | {{DEFAULTSORT:Insulin syringe}} | 43 | {{DEFAULTSORT:Insulin syringe}} |